A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Placebo as an Add-on to Glimepiride in Subjects With Type 2 Diabetes

The purpose of this study is to evaluate the effect of TAK-875 compared to placebo on glycemic control over a 24-week Treatment Period when used as an add-on to glimepiride in addition to diet and exercise.

本研究旨在评估在饮食与运动干预且联合格列美脲（glimepiride）治疗的基础上，额外应用TAK-875相较于安慰剂，在24周治疗周期内对血糖控制的改善效果。